StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Talzenna (talazoparib by Quarter

Talzenna (talazoparib — PARP inhibitor) — International revenues ($M) ($M)

QuarterlyAnnual

Pfizer Talzenna (talazoparib: $17M in Q2 2026, up 41.7% from a year earlier. That is the highest of the 14 quarters on record here.

Latest, Q2 2026
17
Period ended Jun 28, 2026
Change on a year earlier
+41.7%
12 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
10
Documents cited below

Where the Q2 2026 figure comes from

“|| Talzenna | 57 | 46 | 24% | 23% | 40 | 34 | 17% | 17 | 12 | 46% | 41%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTalzenna (talazoparib — PARP inhibitor) — International revenues ($M) ($M)Year on yearSource
Q2 2026Jun 28, 202617+41.7%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 202614+27.3%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 202513+44.4%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 202514+75.0%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 202512+71.4%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2025Mar 30, 202511+83.3%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 20249+50.0%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 20248+14.3%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 20247+40.0%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 202460.0%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 20236–Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 20237–Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2023Jul 2, 20235–Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2023Apr 2, 20236–Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗

Breakdown

What makes up talzenna (talazoparib

Cite this data

StockData. (2026). Pfizer Talzenna (talazoparib ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/talzenna-intl

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.